Extracellular matrix protein ITGBL1 promotes ovarian cancer cell migration and adhesion through Wnt/PCP signaling and FAK/SRC pathway.
Despite the advances in cancer treatment and the progresses in tumor biological, ovarian cancer remains a bad situation. In current study, we found a novel extracellular matrix protein, ITGBL1, which is highly expressed in ovarian cancer tissues by immunohistochemistry examination. The expression pattern of ITGBL1 in malignant tissues inspired us to investigate its role in ovarian cancer progression. Both loss- and gain-function assays revealed that ITGBL1 could promote ovarian cancer cell migration and adhesion. As it's a secreted protein, we further used recombinant ITGBL1 protein treated cancer cells and found that ITGBL1 promotes cell migration and adhesion in a concentration dependent manner. Furthermore, we found that ITGBL1 not only influences the activity of Wnt/PCP signaling but also affects FAK/src pathway in vitro. Taken together, our results suggest that highly expressed ITGBL1 could promotes cancer cell migration and adhesion in ovarian cancer and as a secreted protein, ITGBL1 might be a novel biomarker for ovarian cancer diagnosis.
Department of Out-patient, Affiliated Hospital of Hebei University of Engineering, Handan 056002, Hebei Province, China.
Li
L
Sun
Department of Endocrinology, Affiliated Hospital of Hebei University of Engineering, Handan 056002, Hebei Province, China.
Defeng
D
Wang
Affiliated Hospital of Hebei University of Engineering, Handan 056002, Hebei Province, China.
Xiaotian
X
Li
Department of Biology, The Chinese University of Hong Kong, Shatin, New Territories 999077, Hong Kong, China.
Lingling
L
Zhang
Affiliated Hospital of Hebei University of Engineering, Handan 056002, Hebei Province, China.
Hui
H
Zhang
College of Biology, Hunan University, Changsha 410082, China. Electronic address: yjzhang_hnu@sina.com.
Yingjie
Y
Zhang
D000328:Adult; D000368:Aged; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D005260:Female; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000378:metabolism*; D020868:Gene Silencing / Q000187:drug effects; D006801:Humans; D019012:Integrin beta1 / Q000378:metabolism*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D011994:Recombinant Proteins / Q000494:pharmacology; D060449:Wnt Signaling Pathway / Q000187:drug effects; D055815:Young Adult; D019061:src-Family Kinases / Q000378:metabolism*
D016326:Extracellular Matrix Proteins; C000602818:ITGBL1 protein, human; D019012:Integrin beta1; D011994:Recombinant Proteins; D051416:Focal Adhesion Protein-Tyrosine Kinases; D019061:src-Family Kinases
FAK/src pathway; ITGBL1; Migration and adhesion; Ovarian cancer; RhoA; Wnt/PCP signaling